Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

Summary

This is a long-term open-label safety extension to the Phase 2a study of inhaled QCC374 in adult patients with PAH. This study provides the patients who completed the QCC374X2201 study with the option to continue receiving QCC374. The study will monitor the long-term safety, tolerability and efficacy of QCC374 in patients with PAH.

Timeline

Start

2018-02-01

Primary completion

2018-11-06

Completion

2018-11-06

Outcome

Outcome not reported

Stopped (Business): “Study was terminated early for strategic reasons. Only Part I of the study was completed.”

Drugs

Indications